As the opioid crisis continues to devastate communities worldwide, millions suffering from chronic and neuropathic pain face a critical dilemma: enduring debilitating pain or risking addiction with traditional opioid medications. In this episode of BioBiz Buzz, host Mike Ward explores one of modern medicine's most pressing challenges with Per von Mentzer, CEO of PharmNovo, a pioneering Swedish biotech company developing revolutionary non-addictive pain treatments. 

The conversation delves deep into PharmNovo's groundbreaking approach through their lead candidate PN6047, a selective delta-opioid receptor agonist that promises to deliver powerful pain relief without the addiction risks or sedation effects associated with conventional mu-opioid receptor targeting drugs. Von Mentzer explains how this innovative mechanism specifically addresses neuropathic pain – a particularly challenging condition caused by nerve damage that affects millions of patients with diabetes, chemotherapy side effects, and various injuries.

This episode offers hope for the future of pain management, suggesting that the next five to ten years will witness a fundamental shift toward safer, non-addictive treatments becoming the standard of care. The interview provides both scientific insight into delta-opioid receptor targeting and a realistic perspective on the challenges and opportunities in developing safer pain medications for millions of patients worldwide who desperately need effective alternatives to traditional opioids.

● Feedback

● Subscribe (Get notified when new episodes are available. NO marketing!)

● Disclaimer

● LinkedIn